FY16 Results Presentation

Highlights Revenue ↑11.8% EBITDA-S NPAT Leverage 127.6% 129.7% 1.1x · Final Dividend 6.0 cps Pro forma revenue growth of 11.8% on FY2015 Pro forma EBITDA before SGARA (EBITDA-S) growth of 27.6% to $91.1m • Pro forma NPAT of $49.3m (+29.7%) and statutory NPAT of $25.3m (1) Financial Performance • Leverage reduced to 1.1x of pro forma EBITDA at June 2016(2) Final dividend of 6.0 cents per share (full year 9.0 cps) Results include early adoption of changes to the accounting standard for bearer plants (biological assets). Net impact of $1.2m loss included in pro forma FY2016 NPAT. (1) Pro forma adjustments mainly relate to IPO expenses. A reconciliation between pro forma and statutory results is included in the Appendix (2) Calculated as Net debt / Pro forma EBITDA before SGARA costa fresh is our passion 5

View entire presentation